Modern Bioscience PLC and the University of Dundee to develop novel cancer drug
Re-profiling of rimcazole as an anti-cancer drug based on pioneering science at Dundee
Rimcazole has already been the subject of a clinical trial programme in a different therapeutic area, schizophrenia. The re-profiling of rimcazole for cancer is lower risk than a normal development programme as there is already a considerable amount of pre-clinical and clinical safety data available. These data will allow Modern Biosciences to move into Phase I trials rapidly.
The development of rimcazole for the treatment of cancer has been made possible through the groundbreaking research of Dr Barbara Spruce and her team at the University of Dundee. Dr Spruce's work has focussed on the so-called 'sigma-1 receptor', which has been the subject of considerable pharmaceutical research in the field of psychiatric and neurological disorders.
Dr Spruce and her team were the first to show that agents that bind to the sigma-1 receptor (such as rimcazole) cause tumour cells, but not normal cells, to undergo apoptosis. In recognition of her work, Dr Spruce received the inaugural Gannochy Trust Innovation Award of the Royal Society of Edinburgh in 2003.
The University, with the help of funding from the Wellcome Trust, the North-East Scotland Technology Fund (NESTech) and Scottish Enterprise, has progressed rimcazole to the point of clinical development, a unique achievement within a Scottish university.
Modern Biosciences plans to initiate Phase I dosing studies in healthy volunteers this year. Phase Ib trials, which will monitor tumour growth and several biomarkers that are indicators of disease progression, are expected to start in 2008. Modern Biosciences believes that proof-of-concept data for rimcazole in cancer could be available within two years.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.